Dennis Kannenkeril
Overview
Explore the profile of Dennis Kannenkeril including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delles C, Schmieder R, Daly R, Kannenkeril D, Bosch A, Lauder L, et al.
Hypertension
. 2024 Nov;
82(1):118-125.
PMID: 39569514
Background: Renal denervation lowers blood pressure (BP) in patients with uncontrolled hypertension. We conducted an unbiased genomic screen to identify genetic variants that may associate with BP response to renal...
2.
Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Berner L, Pietschner R, et al.
Clin Res Cardiol
. 2024 Nov;
PMID: 39565386
Background: Impaired endothelial function predicts cardiovascular events. The aim of this study was to analyze the effect of evolocumab on endothelial function in patients with cardiovascular disease. Methods: This was...
3.
Bytyqi V, Kannenkeril D, Striepe K, Bosch A, Karg M, Schmid A, et al.
J Hypertens
. 2024 Nov;
43(3):413-419.
PMID: 39526682
Background: Identifying predictors of blood pressure (BP) response to renal denervation (RDN) is crucial for patient selection. According to Wilder's principle, baseline BP predicts BP change after any antihypertensive intervention....
4.
Bosch A, Rauh M, Striepe K, Schiffer M, Schmieder R, Kannenkeril D
J Hypertens
. 2024 Sep;
42(11):1958-1965.
PMID: 39248112
Background And Hypothesis: Obesity aggravates the risk to develop chronic kidney disease in hypertensive patients. Whether pre-obesity already impairs renal function, renal perfusion and intraglomerular hemodynamics in hypertensive patients is...
5.
Gunes-Altan M, Bosch A, Striepe K, Bramlage P, Schiffer M, Schmieder R, et al.
Cardiovasc Diabetol
. 2024 May;
23(1):184.
PMID: 38811998
Background: Use of sodium-glucose-cotransporter-2 (SGLT2) inhibitors often causes an initial decline in glomerular filtration rate (GFR). This study addresses the question whether the initial decline of renal function with SGLT2...
6.
Gerhalter T, Schilling F, Zeitouni N, Linz P, Baudin P, Kannenkeril D, et al.
Eur Radiol Exp
. 2024 May;
8(1):61.
PMID: 38773044
Background: Clinical magnetic resonance imaging (MRI) studies often use Cartesian gradient-echo (GRE) sequences with ~2-ms echo times (TEs) to monitor apparent total sodium concentration (aTSC). We compared Cartesian GRE and...
7.
Kopp C, Kittler L, Linz P, Kannenkeril D, Horn S, Chazot C, et al.
Kidney Int Rep
. 2024 May;
9(5):1310-1320.
PMID: 38707813
Introduction: Tissue Na overload is present in patients receiving hemodialysis (HD) and is associated with cardiovascular mortality. Strategies to actively modify tissue Na amount in these patients by adjusting the...
8.
Gunes-Altan M, Schmid A, Ott C, Bosch A, Pietschner R, Schiffer M, et al.
Clin Kidney J
. 2024 Jan;
17(1):sfad237.
PMID: 38186882
Background: Renal denervation (RDN) has emerged as an adjacent option for the treatment of hypertension. This analysis of the Erlanger registry aimed to compare the blood pressure (BP)-lowering effects and...
9.
Bosch A, Kannenkeril D, Ott C, Striepe K, Schiffer M, Schmieder R
Nutr Metab Cardiovasc Dis
. 2023 Nov;
34(3):755-762.
PMID: 38000996
Background And Aims: Obesity has been shown to be an independent risk factor for the development of CKD. Little is known about pathways of interaction of visceral fat mass estimated...
10.
Guenes-Altan M, Schmid A, Kannenkeril D, Linz P, Ott C, Bosch A, et al.
Hypertens Res
. 2023 Oct;
47(2):361-371.
PMID: 37880499
Patients with treatment resistant hypertension (TRH) are known to have elevated sodium (Na) content in muscle and skin. Renal denervation (RDN) emerged as an adjacent therapeutic option in this group...